[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590146":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":11,"armGroups":13,"interventions":13,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":17,"collaborators":13,"id":19,"slug":13,"hasResults":20,"nctId":21,"briefTitle":22,"officialTitle":23,"acronym":13,"eligibilityCriteria":24,"healthyVolunteers":20,"sex":25,"minAge":26,"maxAge":13,"enrollmentInfo":27,"targetDuration":13,"studyType":30,"phases":13,"briefSummary":11,"conditions":31,"keywords":13,"overallStatus":33,"whyStopped":13,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":13},{"fullName":5,"class":6},"Radiometer Medical ApS","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"AQT90 FLEX NTproBNP2 Test Kit - Reference Interval Establishment - China","To establish the reference range of the NTproBNP2 Test Kit (time-resolved immunofluorescence method) in apparently healthy Chinese population.","12 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_ONLY","CROSS_SECTIONAL",{"type":18,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100590146",false,"NCT06963619","AQT90 FLEX NTproBNP (N-terminal Pro-brain Natriuretic Peptide) 2 Test Kit - Reference Interval Study Protocol - China","NTproBNP2 Test Kit (Time-Resolved Immunofluorescence Method) Reference Interval Establishment Study Protocol","Inclusion Criteria:\n\nSubjects who meet all the following criteria are eligible for inclusion:\n\n1. Voluntarily participate in this study and sign informed consent;\n2. Body Mass Index (BMI) ≥18.5 and \\\u003C28kg\u002F m2;\n3. Age ≥18 years old;\n4. Through the investigator's consultation with the subjects, evaluate the subjects who meet the requirements of the reference individual of this study (refer to the \"reference individual questionnaire\").\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded:\n\n1. Physical examination, laboratory test\u002Fexamination results meet any of the following:\n\n   * eGFR(estimated glomerular filtration rate) (formula: CKD-EPI, chronic kidney disease epidemiology collaboration) \\\u003C 60 mL\u002Fmin\u002F1.732\n   * Systolic blood pressure ≥130 mm Hg and\u002For diastolic blood pressure ≥80 mmHg\n   * Glycated hemoglobin A1c (HbA1c) ≥ 6.0%; or fasting blood glucose ≥ 7.0 mmol\u002FL\n   * Total cholesterol ≥ 6.22 mmol\u002FL and\u002For triglycerides ≥ 2.26 mmol\u002FL\n   * High-sensitivity troponin: Female: ≥15.6 pg\u002FmL (ng\u002FL), Male: ≥34.2 pg\u002FmL (ng\u002FL)\n   * Electrocardiogram, with obvious abnormalities such as those that may cause cardiac structural changes or risk factors for arrhythmia as assessed by the investigator\n2. Subjects who are unable to provide a sufficient volume (≈2 mL) of EDTAanticoagulated whole blood sample;\n3. Subjects who withdraw informed consent;\n4. Subjects assessed by the investigator as unsuitable for inclusion in this study.","ALL","18 Years",{"count":28,"type":29},240,"ESTIMATED","OBSERVATIONAL",[32],"Diagnostic Tests","NOT_YET_RECRUITING","2025-05-06",{"date":36,"type":37},"2025-05-09","ACTUAL",{"date":39,"type":29},"2025-05",{"date":41,"type":29},"2025-12",{"name":5,"class":6}]